Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection

Lancet. 1990 Apr 14;335(8694):875-7. doi: 10.1016/0140-6736(90)90475-k.

Abstract

Seven chronic carriers of hepatitis B virus (HBV) were studied during treatment with interferon-alpha to determine whether tumour necrosis factor alpha (TNF alpha) or interleukin-1 beta (IL-1 beta) contributed to the elimination of HBV. Four patients responded to interferon-alpha with clearance of HBeAg and permanent inhibition of HBV replication within 3-12 weeks; in each of these patients, the changes were accompanied by substantial rises in spontaneous in-vitro production of TNF alpha and IL-1 beta by peripheral blood mononuclear cells from previously undetectable levels. There was little or no change in spontaneous TNF alpha and IL-1 beta production in the three patients who did not lose HBeAg in response to interferon-alpha. These findings suggest that TNF alpha and IL-1 beta may contribute to the permanent elimination during interferon-alpha treatment of hepatocytes supporting viral infection and that the therapeutic potential of these cytokines is worthy of investigation.

MeSH terms

  • Adult
  • Carrier State / blood
  • Carrier State / microbiology
  • Carrier State / therapy*
  • Chronic Disease
  • DNA, Viral / analysis
  • Drug Evaluation
  • Follow-Up Studies
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / genetics
  • Humans
  • Interferon Type I / therapeutic use*
  • Interleukin-1 / biosynthesis*
  • Interleukin-1beta
  • Lipopolysaccharides / pharmacology
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Peptide Fragments / biosynthesis*
  • Time Factors
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Virus Replication / drug effects

Substances

  • DNA, Viral
  • Interferon Type I
  • Interleukin-1
  • Interleukin-1beta
  • Lipopolysaccharides
  • Peptide Fragments
  • Tumor Necrosis Factor-alpha
  • interleukin-1beta (163-171)